Day: February 9, 2019

Mortgage stress rules determine the 2019 Real estate market outlook

TORONTO, Feb. 09, 2019 (GLOBE NEWSWIRE) — Real Estate Analyst and Vice President of PPS Realty Brokerage, Ali Salarian, believes that mortgage rules may have the most significant influence on the Canadian real estate market direction in 2019. The most prominent real estate market in Canada recorded a 3.4% negative growth as released by the Toronto Real Estate Board (TREB) last month. This negative growth resulted mainly from tighter mortgage stress rules implemented by Office of the Superintendent of Financial Institutions (OSFI) twice: first in late-2016 and second in mid-2017. These rules were implemented in an attempt to improve the

ARLO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Arlo Technologies, Inc. – ARLO

NEW ORLEANS, Feb. 08, 2019 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Arlo Technologies, Inc. (NYSE: ARLO), if they purchased the Company’s shares issued in connection with its August 3, 2018 initial public offering (“IPO”).  This action is pending in the United States District Court for the Northern District of California. What You May Do If you purchased shares of Arlo and would like to

Tetra Bio-Pharma Announces Stock Option Grants

ORLEANS, Ontario, Feb. 08, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE: TBP) (OTB: TBPMF), announces today that it has granted, pursuant to the Company’s stock option plan (the “Plan”), 375,000 options to officers of the Company. Each option entitles its holder to purchase one common share of the Company. 300,000 options will become vested in four 6-month tranches of 75,000 options, are exercisable at a price of $0.69 and will expire on December 24, 2022. 75,000 options vest immediately, are exercisable for a period of four years at a price of $0.69 and will expire

CytoDyn to Present at BIO CEO & Investor Conference 2019 on February 11

VANCOUVER, Washington, Feb. 08, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), CytoDyn, a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it will be presenting a company overview at BIO CEO & Investor Conference 2019 on Monday, February 11, at 9:45 a.m. Eastern time (6:45 a.m. Pacific time).  The conference is being held at the Marriott Marquis Hotel in New York City. The BIO CEO & Investor Conference is an international biotech investor conference focused on established and emerging publicly traded and select private biotech companies.  More information regarding the conference can